1
|
Feng Q, Yi J, Li T, Liang B, Xu F, Peng P. Narrative review of magnetic resonance imaging in quantifying liver iron load. Front Med (Lausanne) 2024; 11:1321513. [PMID: 38362538 PMCID: PMC10867177 DOI: 10.3389/fmed.2024.1321513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Accepted: 01/18/2024] [Indexed: 02/17/2024] Open
Abstract
Objective To summarize the research progress of magnetic resonance imaging (MRI) in quantifying liver iron load. Methods To summarize the current status and progress of MRI technology in the quantitative study of liver iron load through reviewing the relevant literature at home and abroad. Results Different MRI sequence examination techniques have formed a series of non-invasive methods for the examination of liver iron load. These techniques have important clinical significance in the imaging diagnosis of liver iron load. So far, the main MRI methods used to assess liver iron load are: signal intensity measurement method (signal intensity, SI) [signal intensity ratio (SIR) and difference in in-phase and out-of-phase signal intensity], T2/R2 measurement (such as FerriScan technique), ultra-short echo time (UTE) imaging technique, and susceptibility weighted imaging (including conventional susceptibility weighted imaging) (SWI), quantitative susceptibility mapping (QSM), T2*/R2* measurement, Dixon and its derivative techniques. Conclusion MRI has become the first choice for the non-invasive examination of liver iron overload, and it is helpful to improve the early detection of liver injury, liver fibrosis, liver cirrhosis and liver cancer caused by liver iron overload.
Collapse
Affiliation(s)
- Qing Feng
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Jixing Yi
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Tao Li
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Bumin Liang
- School of International Education, Guangxi Medical University, Nanning, China
| | - Fengming Xu
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| |
Collapse
|
2
|
Xu F, Li D, Tang C, Liang B, Guan K, Liu R, Peng P. Magnetic resonance imaging assessment of the changes of cardiac and hepatic iron load in thalassemia patients before and after hematopoietic stem cell transplantation. Sci Rep 2023; 13:19652. [PMID: 37950037 PMCID: PMC10638442 DOI: 10.1038/s41598-023-46524-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 11/02/2023] [Indexed: 11/12/2023] Open
Abstract
To investigate the value of T2* technique on 3.0 T magnetic resonance imaging (MRI) in evaluating the changes of cardiac and hepatic iron load before and after hematopoietic stem cell transplantation (HSCT) in patients with thalassemia (TM), the 141 TM patients were divided into 6 group for subgroup analysis: 6, 12, 18, 24 and > 24 months group, according to the postoperative interval. The T2* values of heart and liver (H-T2*, L-T2*) were quantified in TM patients before and after HSCT using 3.0 T MRI T2* technology, and the corresponding serum ferritin (SF) was collected at the same time, and the changes of the three before and after HSCT were compared. The overall H-T2* (P = 0.001) and L-T2* (P = 0.041) of patients after HSCT were higher than those before HSCT (mean relative changes = 19.63%, 7.19%). The H-T2* (P < 0.001) and L-T2* (P < 0.001) > 24 months after HSCT were significantly higher than those before HSCT (mean relative changes = 69.19%, 93.73%). The SF of 6 months (P < 0.001), 12 months (P = 0.008), 18 months (P = 0.002) and > 24 months (P = 0.001) were significantly higher than those before HSCT (mean relative changes = 57.93%, 73.84%, 128.51%, 85.47%). There was no significant improvement in cardiac and liver iron content in TM patients within 24 months after HSCT, while the reduction of cardiac and liver iron content in patients is obvious when > 24 months after HSCT.
Collapse
Affiliation(s)
- Fengming Xu
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Da Li
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Cheng Tang
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
- NHC Key Laboratory of Thalassemia Medicine (Guangxi Medical University), Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Bumin Liang
- School of International Education, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Kaiming Guan
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Rongrong Liu
- Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
- NHC Key Laboratory of Thalassemia Medicine (Guangxi Medical University), Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
| |
Collapse
|
3
|
Li JC, Chu Y, Yi BD, Chen FY, Huang NG, Liang B. Nano-hydroxyapatite/Polyamide 66 cage in anterior cervical corpectomy and fusion: a comprehensive systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2023; 27:9648-9659. [PMID: 37916330 DOI: 10.26355/eurrev_202310_34136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
OBJECTIVE This study aimed to conduct a meta-analysis to compare the effectiveness and safety between titanium mesh cage (TMC) and nano-hydroxyapatite/polyamide 66 cage (n-HA/PA66) in the surgical treatment of cervical spondylotic myelopathy (CSM) through anterior cervical corpectomy and fusion (ACCF). MATERIALS AND METHODS We implemented a comprehensive search strategy across multiple databases, including Wanfang, China Knowledge Network, China Biomedical Literature Database, Wipu, PubMed, Cochran, Embase, and Web of Science. To ensure a thorough examination of available literature, the databases were searched from their inception to January 2023. Two independent researchers evaluated the quality of the included studies by using established criteria. We used RevMan 5.4 (Review Manager Web, The Cochrane Collaboration, Copenhagen, Denmark) to facilitate data extraction and analysis. RESULTS This analysis included seven controlled clinical studies. The meta-analysis results showed no statistically significant differences between the two groups in terms of operating time, intraoperative bleeding, preoperative Japanese Orthopedic Association (JOA) score, preoperative visual analog scale (VAS) score, preoperative and final follow-up C2-7 Cobb angles, and intervertebral fusion rate (p > 0.05). However, a significant difference was observed between the two groups in terms of the final follow-up JOA [MD = 0.77, 95% CI (0.58, 0.97), p < 0.00001], VAS [MD = -0.50, 95% CI (-0.71, -0.30), p < 0.00001], and sedimentation rate [RR = 0.30, 95% CI (0.18, 0.48), p < 0.00001]. CONCLUSIONS The use of n-HA/PA66 in ACCF for treating CSM is safe and effective treatment with positive clinical efficacy. In addition, n-HA/PA66 has both effective clinical efficacy and significantly lower fusion settling rates compared to TMC.
Collapse
Affiliation(s)
- J-C Li
- Department of Orthopaedics, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
| | | | | | | | | | | |
Collapse
|
4
|
Fan J, Sun Y, Liang B, Zhang X, Xiao C, Huang Z. [Role of gut microbiota in perioperative neurocognitive disorders after cardiopulmonary bypass surgery in rats with humanized gut flora]. Nan Fang Yi Ke Da Xue Xue Bao 2023; 43:964-969. [PMID: 37439168 DOI: 10.12122/j.issn.1673-4254.2023.06.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/14/2023]
Abstract
OBJECTIVE To investigate whether gut microbiota disturbance after cardiopulmonary bypass (CPB) contributes to the development of perioperative neurocognitive disorders (PND). METHODS Fecal samples were collected from healthy individuals and patients with PND after CPB to prepare suspensions of fecal bacteria, which were transplanted into the colorectum of two groups of pseudo-germ-free adult male SD rats (group NP and group P, respectively), with the rats without transplantation as the control group (n=10). The feces of the rats were collected for macrogenomic sequencing analysis, and serum levels of IL-1β, IL-6 and TNF-α were measured with ELISA. The expression levels of GFAP and p-Tau protein in the hippocampus of the rats were detected using Western blotting, and the cognitive function changes of the rats were assessed with Morris water maze test. RESULTS In all the 3 groups, macrogenomic sequencing analysis showed clustering and clear partitions of the gut microbiota after the transplantation. The relative abundances of Klebsiella in the control group (P < 0.005), Akkermansia in group P (P < 0.005) and Bacteroides in group NP (P < 0.005) were significantly increased after the transplantation. Compared with those in the control group, the rats in group NP and group P showed significantly decreased serum levels of IL-1β, IL-6 and TNF-α and lowered expression levels of GFAP and p-Tau proteins (all P < 0.05). Escape platform crossings and swimming duration in the interest quadrant increased significantly in group NP (P < 0.05), but the increase was not statistically significant in group N. Compared with those in group P, the rats in group NP had significantly lower serum levels of IL-1β, IL-6 and TNF-α and protein expressions of GFAP and p-Tau (all P < 0.05) with better performance in water maze test (P < 0.05). CONCLUSION In patients receiving CPB, disturbances in gut mirobiota contributes to the development of PND possibly in relation with inflammatory response.
Collapse
Affiliation(s)
- J Fan
- Department of Anesthesiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China
| | - Y Sun
- Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang 110016, China
| | - B Liang
- Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang 110016, China
| | - X Zhang
- Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang 110016, China
| | - C Xiao
- Health Service Team, No.96852 Troop of PLA, Shenyang 110124, China
| | - Z Huang
- Department of Anesthesiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China
| |
Collapse
|
5
|
Xu F, Peng Y, Xie H, Liang B, Yang G, Zhao F, Liu Y, Peng P. A multicenter study on the quantification of liver iron concentration in thalassemia patients by means of the MRI T 2* technique. Front Med (Lausanne) 2023; 10:1180614. [PMID: 37275360 PMCID: PMC10235725 DOI: 10.3389/fmed.2023.1180614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 04/21/2023] [Indexed: 06/07/2023] Open
Abstract
Objective To investigate the feasibility and accuracy of quantifying liver iron concentration (LIC) in patients with thalassemia (TM) using 1.5T and 3T T2* MRI. Methods 1.5T MRI T2* values were measured in 391 TM patients from three medical centers: the T2* values of the test group were combined with the LIC (LICF) provided by FerriScan to construct the curve equation. In addition, the liver 3T MRI liver T2* data of 55 TM patients were measured as the 3T group: the curve equation of 3T T2* value and LICF was constructed. Results Based on the test group LICF (0.6-43 mg/g dw) and the corresponding 1.5T T2* value, the equation was LICF = 37.393T2*∧(-1.22) (R2 = 0.971; P < 0.001). There was no significant difference between LICe - 1.5T and LICF in each validation group (Z = -1.269, -0.977, -1.197; P = 0.204, 0.328, 0.231). There was significant consistency (Kendall's W = 0.991, 0.985, 0.980; all P < 0.001) and high correlation (rs = 0.983, 0.971, 0.960; all P < 0.001) between the two methods. There was no significant difference between the clinical grading results of LICe - 1.5T and LICF in each validation group (χ2 = 3.0, 4.0, 2.0; P = 0.083, 0.135, 0.157), and there was significant consistency between the clinical grading results (Kappa's K = 0.943, 0.891, 0.953; P < 0.001). There was no statistical correlation between the LICF (≥14 mg/g dw) and the 3T T2* value of severe iron overload (P = 0.085). The LICF (2-14 mg/g dw) in mild and moderate iron overload was significantly correlated with the corresponding T2* value (rs = -0.940; P < 0.001). The curve equation constructed from LICF and corresponding 3T T2* values in this range is LICF = 18.463T2*∧(-1.142) (R2 = 0.889; P < 0.001). There was no significant difference between LICF and LICe - 3T in the mild to moderate range (Z = -0.523; P = 0.601), and there was a significant correlation (rs = 0.940; P < 0.001) and significant consistency (Kendall's W = 0.970; P = 0.008) between them. LICe - 3T had high diagnostic efficiency in the diagnosis of severe, moderate, and mild liver iron overload (specificity = 1.000, 0.909; sensitivity = 0.972, 1.000). Conclusion The liver iron concentration can be accurately quantified based on the 1.5T T2* value of the liver and the specific LIC-T2* curve equation. 3T T2* technology can accurately quantify mild-to-moderate LIC, but it is not recommended to use 3T T2* technology to quantify higher iron concentrations.
Collapse
Affiliation(s)
- Fengming Xu
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Yuzhao Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Hanhong Xie
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Bumin Liang
- School of International Education, Guangxi Medical University, Nanning, Guangxi, China
| | - Gaohui Yang
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Fanyu Zhao
- Department of Radiology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
| | - Yu Liu
- Department of Radiology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning, Guangxi, China
| |
Collapse
|
6
|
Xu F, Feng Q, Yi J, Tang C, Lin H, Liang B, Luo C, Guan K, Li T, Peng P. α- and β-Genotyping of Thalassemia Patients Based on a Multimodal Liver MRI Radiomics Model: A Preliminary Study in Two Centers. Diagnostics (Basel) 2023; 13:diagnostics13050958. [PMID: 36900102 PMCID: PMC10000720 DOI: 10.3390/diagnostics13050958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 02/17/2023] [Accepted: 02/28/2023] [Indexed: 03/06/2023] Open
Abstract
BACKGROUND So far, there is no non-invasive method that can popularize the genetic testing of thalassemia (TM) patients on a large scale. The purpose of the study was to investigate the value of predicting the α- and β- genotypes of TM patients based on a liver MRI radiomics model. METHODS Radiomics features of liver MRI image data and clinical data of 175 TM patients were extracted using Analysis Kinetics (AK) software. The radiomics model with optimal predictive performance was combined with the clinical model to construct a joint model. The predictive performance of the model was evaluated in terms of AUC, accuracy, sensitivity, and specificity. RESULTS The T2 model showed the best predictive performance: the AUC, accuracy, sensitivity, and specificity of the validation group were 0.88, 0.865, 0.875, and 0.833, respectively. The joint model constructed from T2 image features and clinical features showed higher predictive performance: the AUC, accuracy, sensitivity, and specificity of the validation group were 0.91, 0.846, 0.9, and 0.667, respectively. CONCLUSION The liver MRI radiomics model is feasible and reliable for predicting α- and β-genotypes in TM patients.
Collapse
Affiliation(s)
- Fengming Xu
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
| | - Qing Feng
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital, Liuzhou 545005, China
| | - Jixing Yi
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital, Liuzhou 545005, China
| | - Cheng Tang
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
| | - Huashan Lin
- Department of Pharmaceutical Diagnosis, GE Healthcare, Changsha 410005, China
| | - Bumin Liang
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
- School of International Education, Guangxi Medical University, Nanning 530021, China
| | - Chaotian Luo
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
| | - Kaiming Guan
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
| | - Tao Li
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital, Liuzhou 545005, China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
- NHC Key Laboratory of Thalassemia Medicine, Guangxi Medical University, Nanning 530021, China
- Correspondence: ; Tel.: +86-150-7882-2492
| |
Collapse
|
7
|
Yi WW, Guo XQ, Xu Y, Liang B, Song P. A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2023; 27:2591-2604. [PMID: 37013777 DOI: 10.26355/eurrev_202303_31796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
OBJECTIVE Non-small cell lung cancer (NSCLC) ranks high in the incidence of malignant tumors, with limited treatment options and poor prognosis. Ferroptosis is a newly discovered cell death mechanism based on iron and reactive oxygen species (ROS). The role of ferroptosis-related long non-coding RNAs (lncRNAs) and associated prognostic mechanisms in NSCLC require investigation. MATERIALS AND METHODS We constructed a prognostic multi-lncRNA signature based on ferroptosis-related differentially expressed lncRNAs in NSCLC. The levels of ferroptosis-related lncRNA in normal lung cells and lung adenocarcinoma cells were verified by RT-PCR. RESULTS We identified eight differentially expressed lncRNAs associated with NSCLC prognosis. The expression of AC125807.2, AL365181.3, AL606489.1, LINC02320, and AC099850.3 was upregulated, while SALRNA1, AC026355.1, and AP002360.1 were downregulated in NSCLC cell lines. Kaplan-Meier analysis showed that a high-risk patient group was associated with poor NSCLC prognosis. A risk assessment model based on ferroptosis-related lncRNAs was superior to NSCLC prognosis based on traditional clinicopathological features. Gene Set Enrichment Analysis (GSEA) identified immune- and tumor-related pathways in low-risk group patients. In addition, The Cancer Genome Atlas (TCGA) showed that T cell function during APC co-inhibition, APC co-stimulation, chemokine receptor (CCR), MHC class I, parainflammation, T cell co-inhibition, and check-point expression differed significantly between low- and high-risk groups. M6A-related mRNA comparisons between these groups also revealed significant differences in ZC3H13, RBM15, and METTL3 expression. CONCLUSIONS Our new model of lncRNA-associated ferroptosis effectively predicted NSCLC prognoses.
Collapse
Affiliation(s)
- W-W Yi
- Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
| | | | | | | | | |
Collapse
|
8
|
Yi J, Xu F, Li T, Liang B, Li S, Feng Q, Long L. Quantitative study of 3T MRI qDixon-WIP applied in pancreatic fat infiltration in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2023; 14:1140111. [PMID: 36875489 PMCID: PMC9981945 DOI: 10.3389/fendo.2023.1140111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Accepted: 02/02/2023] [Indexed: 02/19/2023] Open
Abstract
OBJECTIVE To investigate the application value of 3T MRI qDixon-WIP technique in the quantitative measurement of pancreatic fat content in patients with type 2 diabetes mellitus (T2DM). METHODS The 3T MRI qDixon-WIP sequence was used to scan the livers and the pancreas of 47 T2DM patients (experimental group) and 48 healthy volunteers (control group). Pancreatic fat fraction (PFF), hepatic fat fraction (HFF), Body mass index (BMI) ratio of pancreatic volume to body surface area (PVI) were measured. Total cholesterol (TC), subcutaneous fat area (SA), triglyceride (TG), abdominal visceral fat area (VA), high density lipoprotein (HDL-c), fasting blood glucose (FPC) and low-density lipoprotein (LDL-c) were collected. The relationship between the experimental group and the control group and between PFF and other indicators was compared. The differences of PFF between the control group and different disease course subgroups were also explored. RESULTS There was no significant difference in BMI between the experimental group and the control group (P=0.231). PVI, SA, VA, PFF and HFF had statistical differences (P<0.05). In the experimental group, PFF was highly positively correlated with HFF (r=0.964, P<0.001), it was moderately positively correlated with TG and abdominal fat area (r=0.676, 0.591, P<0.001), and it was weakly positively correlated with subcutaneous fat area (r=0.321, P=0.033). And it had no correlation with FPC, PVI, HDL-c, TC and LDL-c (P>0.05). There were statistical differences in PFF between the control group and the patients with different course of T2DM (P<0.05). There was no significant difference in PFF between T2DM patients with a disease course ≤1 year and those with a disease course <5 years (P>0.05). There were significant differences in PFF between the groups with a disease course of 1-5 years and those with a disease course of more than 5 years (P<0.001). CONCLUSION PVI of T2DM patients is lower than normal, but SA, VA, PFF, HFF are higher than normal. The degree of pancreatic fat accumulation in T2DM patients with long disease course was higher than that in patients with short disease course. The qDixon-WIP sequence can provide an important reference for clinical quantitative evaluation of fat content in T2DM patients.
Collapse
Affiliation(s)
- Jixing Yi
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, China
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital Guangxi Zhuang Autonomous Region, Liuzhou, China
| | - Fengming Xu
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, China
| | - Tao Li
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital Guangxi Zhuang Autonomous Region, Liuzhou, China
| | - Bumin Liang
- School of International Education, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, China
| | - Shu Li
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital Guangxi Zhuang Autonomous Region, Liuzhou, China
| | - Qing Feng
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Worker’s Hospital Guangxi Zhuang Autonomous Region, Liuzhou, China
| | - Liling Long
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, China
- *Correspondence: Liling Long,
| |
Collapse
|
9
|
Dong X, Tong F, Zhang R, Liang B, Zhai W, Wang S, Fan J, Wang Y, Huang Y. 128P Neoadjuvant durvalumab plus chemotherapy in stage III non-small cell lung cancer: A phase II single-center exploratory study. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
10
|
Yi Y, Sun X, Liang B, Liu G, Wu P, Meyerholz D, Engelhardt J. 257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00947-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
11
|
Wang Y, Shi T, Deng J, Wu J, Qu Y, Zhang Y, Zhu X, Liang B, Yu Q, Du H, Jie L. AB0390 COST-EFFECTIVENESS OF IGURATIMOD IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BY USING A CLAIMS-BASED ALGORITHM: RETROSPECTIVE ANALYSIS OF REAL‑WORLD DATA. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIguratimod (IGU), as one of the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), has been approved by National Medical Products Administration (NMPA) to treat Rheumatoid arthritis (RA).ObjectivesThis study aimed to compare the cost-effectiveness of well-established RA therapies using a claims-based algorithm in RA patients.MethodsAn electronic medical record (EMR) database from Zhujiang Hospital was utilized to estimate the cost-effectiveness of medication for RA patients, including IGU with MTX, biological DMARDs (bDMARDs) with MTX, and MTX alone for more than 6 months from 2014 to 2020. Patients who were deemed effective must meet all the following criteria according to the algorithm, high adherence; no bDMARDs or IGU switch or addition; no prescription of new csDMARDs; no increase in dose or frequency of index drug; no new use of chronic glucocorticoids or increase in glucocorticoid dose; and no more than one glucocorticoid injection. Average cost was calculated by summing total cost of effective treatment and dividing by number of patients achieving efficacy in each group.ResultsA total of 263 patients were included in the analysis. Based on a claims-based algorithm, the effective rate was 27.1 % (26/96) for IGU with MTX group, 11.2% (7/62) for bDMARDs with MTX group, and 13.3% (14/105) for MTX alone group, respectively. Average cost of effective treatment was $833.46 for IGU with MTX therapy, $2554.57 for bDMARDs with MTX therapy, and $171.48 for MTX alone (Table 1).Table 1.Effectiveness and Cost per Effectively Treated Patient with RACriteriaAll patients (n=263)IGU with MTX group(n=96)bDMARDs with MTX group (n=62)MTX (n=105)Effectiveness:no. of patients (%)a47(17.87%)26 (27.1%)7 (11.2/%)14 (13.3%)Cost of all RA-related medication per effectively treated patient(SD)$892.75(911.57)$833.46 (252.67)$2554.5 (1273.13)$171.4 (110.33)Average cost of all RA medications postindex (excluding biologic DMARDs) per patient (SD)b$146.38(114.60)$148.81 (123.12)$86.90 (74.53)$171.4 (110.33)Average cost of only biologicDMARDs postindex per patient (SD)b$746.38(926.35)$684.27(188.67)$2468.67(1285.91)/a χ2showed significant difference in percentage effectiveness for the original algorithm (p<0.05).bMedication cost was 2020 U.S. dollars.ConclusionIGU with MTX therapy was revealed to be both effective and modestly priced, which seemed to be a cost-effective strategy for RA therapy and warranted further cost-effectiveness investigation.References[1](2018) [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi 57 (4), 242-251. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.04.004[2]Hitchon, C. A., & El-Gabalawy, H. S. (2011). The synovium in rheumatoid arthritis. The open rheumatology journal, 5, 107–114. https://doi.org/10.2174/1874312901105010107[3]Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., … van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the rheumatic diseases, 79(6), 685–699. https://doi.org/10.1136/annrheumdis-2019-216655[4]Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al-Gibbawi, M., Baker, J. F., … Akl, E. A. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research, 73(7), 924–939. https://doi.org/10.1002/acr.24596Disclosure of InterestsNone declared
Collapse
|
12
|
Hua G, Zhang X, Zhang M, Wang Q, Chen X, Yu R, Bao H, Liu J, Wu X, Shao Y, Liang B, Lu K. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. ESMO Open 2022; 7:100337. [PMID: 35123209 PMCID: PMC8818928 DOI: 10.1016/j.esmoop.2021.100337] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 11/01/2021] [Accepted: 11/15/2021] [Indexed: 12/11/2022] Open
Abstract
Background Sequential treatment with different generations of anaplastic lymphoma kinase (ALK) inhibitors have been widely applied to ALK-positive lung cancer; however, resistance mutations inevitably developed. Further characterization of ALK resistance mutations may provide key guidance to subsequent therapies. Here we explored the emergence of secondary ALK mutations during sequential ALK tyrosine kinase inhibitor (TKI) treatment in a real-world study of Chinese lung adenocarcinoma (ADC) patients. Methods A clinical-genomic database was queried for lung ADC patients with at least one ALK inhibitor treatment and at least one plasma sample collected following ALK inhibitor treatment. Targeted genome profiling was performed with a 139-gene panel in baseline tumor tissue and serial plasma samples of patients. Results A total of 116 patients met inclusion criteria. ALK G1202R was more common in patients with echinoderm microtubule-associated protein-like 4 (EML4)-ALK v3 fusion, whereas ALK L1196M was more common in v1. TP53 mutant patients were significantly associated with harboring multiple ALK resistance mutations (P = 0.03) and v3+/TP53 mutant patients had the highest rate of multiple ALK resistance mutations. The sequential use of ALK TKI led to an increased incidence of concurrent ALK mutations along the lines of therapies. Alectinib had a lower rate (9%) harboring ALK resistance mutation as first-line ALK TKI compared with crizotinib (36%). ALK compound mutations identified included ALK D1203N/L1196M, ALK G1202R/L1196M, and ALK G1202R/F1174C, which may be lorlatinib resistant. Using paired pretreatment and post-treatment samples, we identified several ALK-independent resistance-related genetic alterations, including PTPRD and CNKN2A/B loss, MYC, MYCN and KRAS amplification, and EGFR19del. Conclusions Sequential postprogression plasma profiling revealed that increased lines of ALK inhibitors can accelerate the accumulation of ALK resistance mutations and may lead to treatment-refractory compound ALK mutations. The selection for optimal first-line TKI is very important to achieve a more efficacious long-term strategy and prevent the emergence of on-target resistance, which may provide guidance for clinical decision making. ALK resistance mutations were differentially enriched in the setting of EML4-ALK v1/v3 and TP53 status. Serial liquid biopsies NGS depicted accumulation of multiple ALK secondary mutations during sequential ALK treatments. Several lorlatinib-resistant ALK compound mutations and ALK-independent resistance genetic alterations were identified.
Collapse
Affiliation(s)
- G Hua
- Department of Cardiothoracic Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China
| | - X Zhang
- Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - M Zhang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Q Wang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - X Chen
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
| | - R Yu
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
| | - H Bao
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
| | - J Liu
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
| | - X Wu
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
| | - Y Shao
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China; School of Public Health, Nanjing Medical University, Nanjing, China
| | - B Liang
- Department of Respiratory Medicine, Foshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Foshan, China.
| | - K Lu
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
| |
Collapse
|
13
|
Shen J, Shan J, Liang B, Zhang D, Tang H, Zhong L, Li M. Effects of Atomoxetine Hydrochloride on Regulation of Lifespan in Drosophila Model. J Nutr Health Aging 2022; 26:203-208. [PMID: 35166316 DOI: 10.1007/s12603-022-1741-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Nootropics (smart drugs) are used by students to enhance cognitive performance which have been reported times in recent years. However, some of the nootropics are central nervous system stimulants which are very likely to lead to addiction or complications such as vomiting and dizziness. Are there nootropics that can improve learning behavior while having potential positive effect on health? Here, we reported that Atomoxetine (ATX) has sex-specific effect on prolonging the life span of female Drosophila melanogaster. Further study indicated that ATX enhanced female resistance to heat stress and their vertical climbing ability, but it did decrease the number of eggs laid. ATX increased food-intake and sleep time both of females and males, and significantly reduced the 24h spontaneous activity of females and males. Our results present the sex dimorphic effect of ATX on life span regulation in Drosophila, and support further research on the beneficial role of ATX and the mechanisms in other animal models.
Collapse
Affiliation(s)
- J Shen
- Jie Shen, Department of Biomedical Engineering, College of Artificial Intelligence, Hangzhou Dianzi University, Hangzhou, China 310018,
| | | | | | | | | | | | | |
Collapse
|
14
|
Liu X, Luo M, Pei Y, Bao B, Cai Q, Liang B, Bartels D, Perez-Garcia C, Engelhardt J. 663: LUNAR efficiently delivers mRNA into ferret airway epithelial cells in vitro and in vivo. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02086-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Liu X, Luo M, Hallée S, Cai Q, Liang B, Bartels D, Guay D, Engelhardt J. 666: Genome editing in ferret airway epithelia mediated by CRISPR/nucleases delivered with amphiphilic peptide shuttles. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02089-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Yi Y, Sun X, Liang B, Wu P, Wang H, Norris A, Engelhardt J. 628: Abnormalities in glucose metabolism differ between early and late onset of CF pancreatitis in CFTR-G551D-KI ferrets. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02051-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Yuan F, Gasser G, Sun X, He N, Yu M, Liang B, Engelhardt J. 385: Generation of FOXi1-KO ferrets using CRISPR/Cas9 gene editing to inform pulmonary ionocyte biology. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01809-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Evans T, Liang B, Yan Z, Sun X, Yi Y, Vegter A, Guo L, Yang Y, Feng Z, Park S, Qi L, Bartels D, Gibson K, Meyerholz D, Engelhardt J. 658: In utero CFTR modulator therapy protects from meconium ileus and improves postnatal survival in F508del ferrets. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02081-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Sun X, Liang B, Yi Y, Wang H, Wu P, Bartels D, Engelhardt J. 613: Impact of VX-770 on fertility, pregnancy, and lactation in second-generation CFTRG551D/G551D ferrets. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02036-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Abstract
Periodontitis is a chronic inflammatory condition characterized by destruction of nonmineralized and mineralized connective tissues. This study evaluated the role of Trem1 (triggering receptors expressed on myeloid cells 1) in periodontitis by influencing polarization of M1 macrophages through the STAT3/HIF-1α signaling pathway. Trem1 was significantly upregulated in the gingival tissues of patients with periodontitis, as identified by high-throughput RNA sequencing, and positively correlated with levels of M1 macrophage-associated genes. The results of flow cytometry, Western blotting, and reverse transcription quantitative polymerase chain reaction showed that knockdown of Trem1 in RAW 264.7 cells decreased polarization of M1 macrophages and increased polarization of M2 macrophages, while overexpression of Trem1 exerted an opposite effect. Furthermore, a mouse model of Trem1 knockout periodontitis exhibited limited infiltration of macrophages and decreased expression levels of M1 macrophage-associated genes in periodontitis lesions and bone marrow-derived macrophages. Importantly, we found that Trem1 could regulate polarization of M1 macrophages through STAT3/HIF-1α signaling as evidenced by RNA sequencing. Moreover, inhibition of Trem1 and HIF-1α could suppress the expression level of proinflammatory cytokine (interleukin 1β) and upregulate the expression level of anti-inflammatory cytokine (interleukin 10) in periodontitis. Collectively, we identified that the Trem1/STAT3/HIF-1α axis could regulate polarization of M1 macrophages and is a potential candidate in the treatment of periodontitis.
Collapse
Affiliation(s)
- D Wu
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - Y Weng
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - Y Feng
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - B Liang
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - H Wang
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - L Li
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| | - Z Wang
- Department of Implantology, School and Hospital of Stomatology, Tongji University, Shanghai, China.,Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, China
| |
Collapse
|
21
|
Song P, Wang QB, Liang B, Jiang SJ. Advances in research on the relationship between the gut microbiome and cancer. Eur Rev Med Pharmacol Sci 2021; 25:5104-5112. [PMID: 34486684 DOI: 10.26355/eurrev_202108_26521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The objective of this review is to provide currently available information on the relationship between the gut microbiome and cancer. MATERIALS AND METHODS In this mini-review, we explored the PubMed, EMBASE, and Google Scholar electronic databases, with regards to the searching terms "gut microbiome, cancer, intestinal flora, immunotherapy, immune checkpoint inhibitor". By reviewing and analyzing the literature, we analyzed how the bacterial microbiome influences the immune system and cancer, as well as how changes in symbiotic flora may be applied to improve the efficacy of cancer immunotherapy. RESULTS The microbiota is related to the development of tumors and may promote canceration. In recent years, a number of studies have confirmed the influence of intestinal flora on immune checkpoint inhibitors in cancer patients, and studies have also shown the link between the intestinal microbiome and treatment-related immune toxicity. Antibiotics, proton pump inhibitors, and hormones affect the composition of the gut microbiota. CONCLUSIONS Intestinal flora is closely related to cancer. Intestinal flora has a certain impact on cancer occurrence, cancer treatment, cancer immunotherapy efficacy, and side effects.
Collapse
Affiliation(s)
- P Song
- Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
| | | | | | | |
Collapse
|
22
|
Borazanci E, Al Hallak M, Eder J, Golan T, Pant S, Perets R, Markel G, Schickler M, Reuveni H, Jin L, Liang B. 1027TiP A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
23
|
Shi L, Zhou C, Long X, Li H, Chen C, Peng C, Li P, Li J, Gu S, Liang B, Liao W. 949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.169] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
24
|
Zhao N, Yu MJ, Xu J, Wang HY, Liang B, Ding L, Zhang YX, Du K, Leng BL. microRNA-29b mediates Th17/Treg imbalance in chronic obstructive pulmonary disease by targeting IL-22. J BIOL REG HOMEOS AG 2021; 35:987-999. [PMID: 34159768 DOI: 10.23812/21-15-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Chronic obstructive pulmonary disease (COPD) represents a chronic inflammatory disorder of the airways induced mainly by cigarette smoking. In the current study, cigarette smoke extract (CSE) was used to develop an in vitro COPD model using human bronchial epithelium (HBE) cells to expound the possible role of microRNA-29b (miR-29b) in COPD. Firstly, miR-29b and interleukin (IL)-22 expression was assessed in serum of 20 healthy non-smokers, 20 healthy smokers and 20 COPD patients as well as CSE-treated HBE cells. Then, miR-29b and IL-22 expression was altered to evaluate their functions in Th17/Treg ratio. miR-29b inhibited Th17/Treg ratio and levels of IL-22; whereas overexpression of IL-22 reversed these trends. Moreover, rescue experiments found that IL-22 neutralized the repressive effects of miR-29b on Th17/Treg ratio and inflammatory response. Finally, we found that miR-29b blocked the JAK/STAT3 pathway in CSE-treated HBE cells. These data highlighted that miR-29bs modulated Th17/Treg imbalance in CSE-induced experimental COPD through inhibition of IL-22-dependent JAK/STAT3 pathway.
Collapse
Affiliation(s)
- N Zhao
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - M J Yu
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - J Xu
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - H Y Wang
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - B Liang
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - L Ding
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - Y X Zhang
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - K Du
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| | - B L Leng
- Department of Respiratory Medicine, Hangzhou Third Hospital, Hangzhou, Zhejiang, P.R. China
| |
Collapse
|
25
|
Zhang LY, Wang Y, Yang YR, Shao JJ, Liang B. MiR-135a regulates renal fibrosis in rats with diabetic kidney disease through the Notch pathway. Eur Rev Med Pharmacol Sci 2021; 24:1979-1987. [PMID: 32141566 DOI: 10.26355/eurrev_202002_20375] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To explore the influence of micro ribonucleic acid (miR)-135a on the renal fibrosis in rats with diabetic kidney disease (DKD) through the Notch signaling pathway. MATERIALS AND METHODS A total of 30 male Wistar rats weighing 200-220 g were selected and randomly divided into Control group (n=10), diabetes mellitus (DM) group (n=10), and miR-13a inhibitor group (n=10). Streptozotocin (STZ) was intraperitoneally injected daily to establish the DM model in rats of both DM group and miR-135a group, while normal saline was given daily through intraperitoneal injection in rats of Control group. After 4 weeks, the rats in miR-135a inhibitor group were intraperitoneally injected with miR-135a inhibitor, and those in Control and DM groups were administrated with an equal amount of normal saline. Changes in the blood glucose (BG), glycated hemoglobin (GHb), serum creatinine (Scr), triglyceride (TG), and total cholesterol (TC) of rats were evaluated, and the pathological changes in the renal tissues of DM rats were observed via hematoxylin-eosin (HE) staining. Sirius red staining was performed to observe the changes in collagen fibers in the kidney of all groups of rats. The expressions of Notch and Hes1 in the renal tissues of rats in each group were detected using immunohistochemistry. Immunofluorescence assay was employed to detect the positive expression of Notch in the renal tissues of rats. The mRNA expressions of Notch and miR-135a were detected via quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). Finally, Western blotting was conducted to detect the protein expressions of Notch, Notch intracellular domain (NICD) and Hes1. RESULTS Compared with Control group, rats in DM group had substantially raised levels of BG, GHb, Scr, TG, and TC (p<0.05). HE staining showed that the rats in Control group had renal tubular cells with normal morphology and well-defined structure, while those in DM group exhibited evident cavitation in the renal tubular epithelium. Sirius red staining results manifested that the red collagen fibers were evenly distributed with light staining in the glomeruli and renal tubules of rats in Control group. In contrast, the collagen fibers of the glomeruli and renal tubules of rats in DM group exhibited deep and evident red staining. Moreover, compared with DM group, rats in miR-135a inhibitor group had notably faded red staining in the glomeruli and renal tubules of rats, evenly distributed collagen and remarkably decreased fibrotic nodules. According to immunohistochemistry detection results, the protein levels of Notch and Hes1 in the renal tubulointerstitial cells and renal tubular epithelial cells of rats in DM group were markedly higher than those in Control group. Compared with those in DM group, their protein levels were remarkably lowered in miR-135a inhibitor group (p<0.05). Immunofluorescence assay results revealed that the protein level of Notch in the renal tissues of rats in DM group was considerably higher than that in Control group (p<0.05), while its protein level in miR-135a inhibitor group was significantly lower than that in DM group. According to qRT-PCR results, compared with those in Control group, mRNA expressions of Notch mRNA and miR-135a in the rat kidney tissues were substantially raised in DM group (p<0.05), and they were notably lowered in miR-13a inhibitor group compared with those in DM group (p<0.05). Finally, Western blotting results manifested that the protein levels of Notch, NIC, and Hes1 in the renal tissues of rats in DM group were considerably higher than those in Control group (p<0.05), and that their protein expression levels in miR-135a inhibitor group were markedly lower than those in DM group (p<0.05). CONCLUSIONS Inhibition of miR-135a can reduce the renal fibrosis in DKD rats through the Notch pathway.
Collapse
Affiliation(s)
- L-Y Zhang
- Department of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
| | | | | | | | | |
Collapse
|
26
|
Ma J, Cheng L, Wu YY, Cai XY, Liang B, Xiao FL. A retrospective analysis of 925 cases of segmental vitiligo in a Chinese Han population. J Eur Acad Dermatol Venereol 2021; 35:e379-e381. [PMID: 33539593 DOI: 10.1111/jdv.17150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 01/18/2021] [Accepted: 01/27/2021] [Indexed: 12/13/2022]
Affiliation(s)
- J Ma
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China
| | - L Cheng
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China
| | - Y-Y Wu
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China
| | - X-Y Cai
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China
| | - B Liang
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China
| | - F-L Xiao
- Department of Dermatology of First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology, Ministry of Education, Anhui Medical University, Hefei, China.,The Center for Scientific Research of Anhui Medical University, Hefei, China
| |
Collapse
|
27
|
Yuan T, Cai ML, Sheng YM, Ding X, Shen TT, Li WR, Huang H, Liang B, Zhang XJ, Zhu QX. Differentially expressed proteins identified by TMT proteomics analysis in children with verrucous epidermal naevi. J Eur Acad Dermatol Venereol 2021; 35:1393-1406. [PMID: 33428294 DOI: 10.1111/jdv.17112] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 12/04/2020] [Indexed: 12/25/2022]
Abstract
BACKGROUND Verrucous epidermal naevi (VEN) are benign skin tumours, considered keratinocytic epidermal naevi, that appear at birth or early childhood. VEN may display a range of appearances, depending on patient age. Although the number of studies regarding VEN is increasing, the exact mechanism of VEN is still unknown. OBJECTIVES The aim of this study was to analyse the changes in the expression of protein factors in lesions of VEN children by TMT labelling-based quantitative proteomics. METHODS A total of 8 children with VEN (5 for experiment and 3 for validation) and 8 healthy children (5 for experiment and 3 for validation) presented to the Department of Dermatology, the First Affiliated Hospital of Anhui Medical University, Boao Super Hospital, between January 2019 and November 2019. The lesions and lesion-adjacent tissues from children with VEN and naevus-adjacent normal skin tissues from children with pigmented naevi were defined as the VEN group, VENC group and C group, respectively. We performed a proteomics analysis to screen for differentially expressed proteins in the lesions of these individuals. We further performed Western blotting to validate the relative expression levels of nine targeted proteins in the validation group. RESULTS According to the proteomics results, a total of 4970 proteins were identified, and 4770 proteins were quantified. Among these proteins, 586 proteins were up- or downregulated at least 1.3-fold with a P-value < 0.05 (upregulated: 399, downregulated: 187) in lesions between the VEN group and the C group. These proteins played important roles in multiple biological functions, such as cornification, epidermal cell differentiation and neutrophil activation, and formed a complicated protein-protein interaction network. Of the 586 up- or downregulated proteins, nine were selected for further validation. According to Western blotting analysis results, the relative expression levels of Involucrin, NDUFA4, Loricrin, Keratin type II cytoskeletal 6A (Cytokeratin 6A), BRAF, Filaggrin, S100A7 and Desmocollin-3 were significantly upregulated in VEN children and may be associated with skin barrier dysfunction, epidermal cell overgrowth and differentiation, inflammation and immune and oxidative phosphorylation, which are involved in the pathogenesis of VEN. CONCLUSIONS According to TMT-based proteomics and Western blotting results, we identified eight noteworthy proteins, Involucrin, NDUFA4, Loricrin, Keratin type II cytoskeletal 6A, BRAF, Filaggrin, S100A7 and Desmocollin-3, that were upregulated in the lesions of VEN children and may be associated with the pathogenesis of VEN. Our findings provide new starting points for identifying precise pathogenic mechanisms or therapeutic targets for VEN.
Collapse
Affiliation(s)
- T Yuan
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - M-L Cai
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - Y-M Sheng
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - X Ding
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - T-T Shen
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - W-R Li
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - H Huang
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - B Liang
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| | - X-J Zhang
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China.,Department of Dermatology and Venereology, Boao Super Hospital, Qionghai, Hainan, China
| | - Q-X Zhu
- Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.,Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China.,Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui, China
| |
Collapse
|
28
|
Wang C, Guo P, Yang XD, Xie QW, Yin MJ, Jiang KW, Liang B, Shen ZL, Shen K, Wang S, Ye YJ. [Clinicopathological features and prognosis in patients with presacral recurrent rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 2020; 23:461-465. [PMID: 32842425 DOI: 10.3760/cma.j.cn.441530-20200303-00109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinicopathological features and prognostic factors in patients with presacral recurrent rectal cancer (PRRC). Methods: PRRC was defined as recurrence of rectal cancer after radical surgery involving posteriorly the presacral soft tissue, the sacrum/coccyx, and/or sacral nerve root. The diagnosis is confirmed with clinical symptoms (pain of pelvis/back/lower limb, bloody stools, increased frequency of defecation, and abnormal secretions), physical examination of perineal or pelvic masses, radiological findings, colonoscopy with histopathological biopsy, and the evaluation by multi-disciplinary team (MDT). Inclusion criteria: (1) primary rectal cancer undergoing radical surgery without distant metastasis; (2) PRRC was diagnosed; (3) complete inpatient, outpatient and follow-up data. According to the above criteria, clinical data of 72 patients with PRRC in Peking University People's Hospital from January 2008 to December 2017 were retrospectively analyzed. The clinicopathological features and follow-up data were summarized. Cox proportional hazard models was used to analyze the prognostic factors of PRRC. Results: Among 72 patients, 45 were male and 27 were female with a male-to-female ratio of 1.7:1.0. The median age at recurrence was 58 (34 to 83) years and the median interval from surgery to recurrence was 2.0 (0.2 to 17.0) years. The main symptom was pain in 48.6% (35/72) of patients. In addition, gastrointestinal symptoms were found in 25.0% (18/72) of patients. The presacral recurrent sites were presacral fascia in 36 (50.0%) patients, lower sacrum (S3~S5 or coccyx) in 25 (34.7%) patients, and higher sacrum (S1~S2) in 11 (15.3%) patients. Forty-seven (65.3%) patients underwent radical surgery (abdominal resection, abdominoperineal resection, sacrectomy, abdominosacral resection), 12 (16.7%) underwent non-radical surgery (colostomy, cytoreductive surgery), and 13 (18.1%) did not undergo any surgery but only receive palliative chemoradiotherapy and nutritional support treatment. Thirty-three (45.8%) patients received radiotherapy and/or chemotherapy (oxaliplatin, 5-fluorouracil, capecitabine, irinotecan, etc.). All the patients received follow-up, and the median follow-up time was 19 (2 to 72) months. The median overall survival time was 14 (1 to 65) months. The 1- and 3-year overall survival rates were 67.1% and 32.0%, respectively. Univariate analysis showed that age at recurrence (P=0.031) and radical resection (P<0.001) were associated with prognosis. Multivariate analysis demonstrated that radical resection was independent factor of good prognosis (RR=0.140, 95%CI: 0.061-0.322, P<0.001). Conclusions: Patients tend to develop presacral recurrent rectal cancer within 2 years after primary surgery. The main symptom is pain. Patients undergoing radical resection have a relatively good prognosis.
Collapse
Affiliation(s)
- C Wang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - P Guo
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - X D Yang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Q W Xie
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - M J Yin
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - K W Jiang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - B Liang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Z L Shen
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - K Shen
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - S Wang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Y J Ye
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
29
|
Guo P, Wang C, Yang XD, Xie QW, Yin MJ, Jiang KW, Liang B, Shen ZL, Shen K, Yang Y, Guo W, Ye YJ. [Comparison of clinical efficacy among different surgical methods for presacral recurrent rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 2020; 23:466-471. [PMID: 32842426 DOI: 10.3760/cma.j.cn.441530-20200210-00045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the efficacy and prognosis of three surgical methods for presacral recurrent rectal cancer (PRRC). Methods: A retrospective cohort study was carried out. Case inclusion criteria: (1) primary rectal cancer without distant metastasis and undergoing radical surgery; (2) patients undergoing radical surgery after the diagnosis of PRRC; (3) complete inpatient, outpatient and follow-up data. Clinical data of 47 patients meeting the above criteria who underwent operation at the Department of Gastrointestinal Surgery, The Peking University People's Hospital from January 2008 to December 2017 were reviewed and analyzed retrospectively. Of the 47 patients, 31 were male and 16 were female; the mean age was 57 years old; 9 (19.1%) were low differentiation or signet ring cell carcinoma, 38 (80.9%) were medium differentiation; 19 (40.4%) received neoadjuvant therapy. According to operative procedure, 22 patients were in the abdominal/abdominoperineal resection group, 15 in the sacrectomy group and 10 in the abdominosacral resection group. The operative data, postoperative data and prognosis were compared among the three groups. Survival curve was conducted using the Kaplan-Meier method, and log-rank test was used to compare survival difference among three groups. Results: There were no significant differences in baseline data among three groups (all P>0.05). All the 47 patients completed the radical resection successfully. The mean operation time was (4.7±2.1) hours, the median intraoperative blood loss was 600 ml, and the median postoperative hospitalization time was 17 days. Fifteen cases (31.9%) had perioperative complications, of which 3 cases were grade III-IV. There was no perioperative death. The mean operative time was (7.4±1.6) hours in the abdominosacral resection group, (4.9±1.6) hours in the abdominal/abdominoperineal resection group, and (3.0±1.1) hours in the sacroectomy group, with a significant difference (F=25.071, P<0.001). There were no significant differences in intraoperative blood loss, postoperative hospitalization days and perioperative complications among the three groups (all P>0.05). The median follow-up period of all the patients was 24 months, 12 cases (25.5%) developed postoperative dysfunction. The incidence of postoperative dysfunction in the abdominosacral resection group was 5/10, which was higher than 4/15 in the sacrectomy group and 3/22 (13.6%) in the abdominoperineal resection group with statistically significant difference (χ(2)=9.307, P=0.010). The 1-year and 3-year overall survival rates were 86.1% and 40.2% respectively. The 1-year overall survival rates were 86.0%, 86.7% and 83.3%, and the 3-year overall survival rates were 33.2%, 40.0% and 62.5% in the abdominal/abdominoperineal resection group, sacrectomy group and abdominosacral resection group, respectively, whose difference was not statistically significant (χ(2)=0.222, P=0.895). Conclusions: Abdominal/abdominoperineal resection, sacrectomy and abdominosacral resection are all effective for PRRC. Intraoperative function protection should be concerned for patients undergoing abdominosacral resection.
Collapse
Affiliation(s)
- P Guo
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - C Wang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - X D Yang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Q W Xie
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - M J Yin
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - K W Jiang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - B Liang
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Z L Shen
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - K Shen
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| | - Y Yang
- Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China
| | - W Guo
- Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China
| | - Y J Ye
- Department of Gastrointestinal Surgery, Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
30
|
Smith S, Liang B, Mills K, Dick R, Massad L, Hagemann A, Thaker P, Fuh K, McCourt C, Powell M, Mutch D, Kuroki L. Implementation of a care bundle for inpatient management of acute kidney injury among gynecologic oncology patients: Lessons learned from a quality improvement project. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Zhu LY, Zhao SD, Shen ZL, Ye YJ, Yin MJ, Yang XD, Xie QW, Jiang KW, Liang B, Wang S. [Comparative study of functional prognosis of transanal total mesorectal excision and conventional total mesorectal excision based on propensity score matching]. Zhonghua Wai Ke Za Zhi 2020; 58:619-625. [PMID: 32727194 DOI: 10.3760/cma.j.cn112139-20200330-00267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To compare the postoperative functional prognosis of transanal mesorectal excision (taTME) and conventional total mesorectal excision (TME) in rectal cancer. Methods: Totally 49 patients underwent taTME and 478 patients underwent conventional TME at Department of Gastroenterological Surgery, Peking University People's Hospital from January 2015 to December 2019 were retrospectively collected. Propensity score matching method was used to perform 1 versus 1 matching between the taTME and conventional TME groups, and 36 pairs of patients were successfully matched. After matching, the median age of patients in taTME group and conventional TME group was 60.5 (16.0) years and 60.5 (13.0) years (M(Q(R))), respectively, and the proportion of male patients was 66.7% (24/36) and 55.6% (20/36) , respectively. EORTC QLQ-C30 scale was used to assess quality of life, low anterior resection syndrome (LARS) scale and Wexner constipation score were used to evaluate anal function, international prostate symptom score (IPSS) was used to evaluate urinary function,international index of erectile function (IIEF) -5 and female sexual function index (FSFI) score were used to evaluate male and female sexual function, respectively, and generalized anxiety disorder (GAD-7) and patient health questionnaire (PHQ-9) scale were used to evaluate psych function. The t test, Mann-Whitney U test, χ(2) test, and Fisher exact test were used for comparison between groups, and Wilcoxon rank sum test or McNemar test was used for comparison between paired data. Results: There were no significant differences in surgery time, postoperative hospital stays, conversion rate, morbidity rate, surgery cost, and numbers of lymph node yield between the two groups (all P>0.05). Compared with the conventional TME group, the intraoperative blood loss in the taTME group was significantly higher (100 (100) ml vs. 80 (50) ml, U=424.5, P=0.010), the prophylactic stoma rate was significantly higher (96.9%(31/36) vs. 63.6%(21/36), χ(2)=11.218, P<0.01), the total hospitalization cost was significantly lower (74 297.7 (16 746.4) CNY vs. 91 781.3 (26 228.4) CNY, U=413.0, P=0.008). There were no significant differences in anal and urinary function between the two groups (LARS scalescore: Z=-0.513, P=0.608, Wexner constipation score: Z=-0.992, P=0.321, IPSS: Z=-1.807, P=0.071). In terms of psych function, significant difference in GAD-7 scale was seen between the two groups (Z=-2.311, P=0.021), patients with generalized anxiety disorder accounting for 26.7% (8/30) and 46.9% (15/32), respectively. Conclusions: Compared with conventional TME surgery, taTME has a significantly increased blood loss and prophylactic stoma rate. There are no significant difference in the incidence of postoperative anal, urinary, and sexual dysfunction between taTME and conventinal TME. taTME can alleviate the financial burden and general anxiety disorder to a certain extent.
Collapse
Affiliation(s)
- L Y Zhu
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - S D Zhao
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - Z L Shen
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - Y J Ye
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - M J Yin
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - X D Yang
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - Q W Xie
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - K W Jiang
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - B Liang
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| | - S Wang
- Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
32
|
Zhang HG, Pan YW, Feng J, Zeng CT, Zhao XQ, Liang B, Zhang WW. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. Eur Rev Med Pharmacol Sci 2020; 23:2003-2012. [PMID: 30915743 DOI: 10.26355/eurrev_201903_17239] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The aim of this study was to explore the regulatory role of TRIM66 in the development of hepatocellular carcinoma (HCC), and to investigate its underlying mechanism. PATIENTS AND METHODS A total of 88 pairs of HCC tissues and para-cancerous tissues were surgically resected. The expression of TRIM66 was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between TRIM66 expression and clinic-pathologic characteristics of HCC patients was analyzed. Follow-up data of enrolled HCC patients were collected for survival analysis. Subsequently, TRIM66 expression in HCC cells was determined by qRT-PCR as well. By constructing si-TRIM66, the biological performances of transfected HCC cells were determined using cell counting kit-8 (CCK-8), colony formation and transwell assay. Western blot was performed to measure the protein expressions of relative genes in epithelial-mesenchymal transition (EMT) pathway. Finally, HCC cells were co-transfected with si-TRIM66 and pcDNA-E-cadherin, followed by detection of invasive and migratory abilities. RESULTS TRIM66 was highly expressed in HCC tissues compared with that of para-cancerous tissues. High expression of TRIM66 was positively correlated with tumor stage, lymph node metastasis and distant metastasis, whereas not correlated with age and sex of HCC patients. Kaplan-Meier curves revealed that a higher expression of TRIM66 was associated with worse prognosis of HCC. Similarly, TRIM66 was also highly expressed in HCC cells. The knockdown of TRIM66 in HCC cells significantly inhibited the proliferative, invasive and migratory abilities of transfected cells. However, TRIM66 down-regulation significantly induced cell apoptosis. Western blot results showed that TRIM66 knockdown in HCC cells markedly downregulated the protein expressions of E-cadherin, N-cadherin, Vimentin and β-catenin. The inhibited migration and invasion of HCC cells resulted from TRIM66 knockdown were partially reversed by E-cadherin overexpression. CONCLUSIONS TRIM66 is highly expressed in HCC, which is positively correlated with tumor stage, lymph node metastasis and distant metastasis of HCC patients. In addition, TRIM66 promotes the malignant progression of HCC by inhibiting E-cadherin through the EMT pathway.
Collapse
Affiliation(s)
- H-G Zhang
- Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing, China.
| | | | | | | | | | | | | |
Collapse
|
33
|
He M, Zuo X, Liu H, Wang W, Zhang Y, Fu Y, Zhen Q, Yu Y, Pan Y, Qin C, Li B, Yang R, Wu J, Huang Z, Ge H, Wu H, Xu Q, Zuo Y, Chen W, Qin Y, Liu Z, Chen S, Zhang H, Zhou F, Yan H, Yu Y, Yong L, Chen G, Liang B, Cornell RA, Zong L, Wang L, Zou D, Sun L, Bian Z. Genome-wide Analyses Identify a Novel Risk Locus for Nonsyndromic Cleft Palate. J Dent Res 2020; 99:1461-1468. [PMID: 32758111 DOI: 10.1177/0022034520943867] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The 3 major subphenotypes observed in patients with nonsyndromic orofacial clefts (NSOFCs) are nonsyndromic cleft lip only (NSCLO), nonsyndromic cleft lip with palate (NSCLP), and nonsyndromic cleft palate only (NSCPO). However, the genetic architecture underlying NSCPO is largely unknown. Here we performed a 2-stage genome-wide association study (GWAS) on NSCPO and replication analyses of selected variants in other NSOFCs from the Chinese Han population. We identified a novel locus (15q24.3) and a known locus (1q32.2) where variants in or near the gene reached genome-wide significance (2.80 × 10-13 < P < 1.72 × 10-08) in a test for association with NSCPO in a case-control design. Although a variant from 15q24.3 was found to be significantly associated with both NSCPO and NSCLP, the direction of estimated effects on risk were opposite. Our functional annotation of the risk alleles within 15q24.3 coupled with previously established roles of the candidate genes within identified risk loci in periderm development, embryonic patterning, and/or regulation of cellular processes supports their involvement in palate development and the pathogenesis of cleft palate. Our study advances the understanding of the genetic basis of NSOFCs and provides novel insights into the pathogenesis of NSCPO.
Collapse
Affiliation(s)
- M He
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - X Zuo
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - H Liu
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - W Wang
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Y Zhang
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Y Fu
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - Q Zhen
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Y Yu
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - Y Pan
- Jiangsu Key Laboratory of Oral Diseases, School of Stomatology, Nanjing Medical University, Nanjing, Jiangsu, China
| | - C Qin
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - B Li
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - R Yang
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - J Wu
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Z Huang
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - H Ge
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - H Wu
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - Q Xu
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Y Zuo
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - W Chen
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Y Qin
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - Z Liu
- Stomatological Hospital of Nanyang, Nanyang, Henan, China
| | - S Chen
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - H Zhang
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - F Zhou
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - H Yan
- Stomatological Hospital of Xiangyang, Xiangyang, Hubei, China
| | - Y Yu
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - L Yong
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - G Chen
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - B Liang
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - R A Cornell
- Department of Anatomy and Cell Biology, College of Medicine, University of Iowa, Iowa City, IA, USA
| | - L Zong
- Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - L Wang
- Jiangsu Key Laboratory of Oral Diseases, School of Stomatology, Nanjing Medical University, Nanjing, Jiangsu, China
| | - D Zou
- Department of Oral Surgery, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
| | - L Sun
- Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.,Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China.,Key Laboratory of Major Autoimmune Diseases, Anhui Province, Hefei, China
| | - Z Bian
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| |
Collapse
|
34
|
Lenger S, Liang B, Lowder J, Strand E, Chu C. 22: Creation of a surgical skills teaching model for anterior and posterior colporrhaphy. Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.12.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Cheng D, He H, Liang B. A three-microRNA signature predicts clinical outcome in breast cancer patients. Eur Rev Med Pharmacol Sci 2019; 22:6386-6395. [PMID: 30338807 DOI: 10.26355/eurrev_201810_16051] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Breast invasive carcinoma (BRCA) is a complex polygenic disease characterized by molecular and histological heterogeneity. An effort is underway to explore and investigate multiple reliable prognostic markers to improve management of BRCA patients and provide novel therapeutic targets. The aim of the study is to identify the prognostic miRNA signature in BRCA patients. PATIENTS AND METHODS The miRNA-sequencing data and clinical information of BRCA patients were downloaded from The Cancer Genome Atlas (TCGA) database. RESULTS A total of 106 differentially expressed miRNAs were identified between BRCA tissues and matched normal tissues, including 81 up-regulated miRNAs and 25 down-regulated miRNAs. Then, we established a set of three-miRNA signature that was significantly associated with BRCA patients' survival. Using the prognostic three-miRNA signature, we classified the BRCA patients into high-risk and low-risk groups. Multivariate Cox regression demonstrated that the prognostic power of the three-miRNA signature was independent of other clinical variables. Functional enrichment analysis suggested that three prognostic miRNAs may be involved in known BRCA-related KEGG pathways and biological processes. CONCLUSIONS We demonstrated that three-miRNA signature could be a potential biomarker for predicting clinical outcomes for BRCA patients.
Collapse
Affiliation(s)
- D Cheng
- Transfusion Department, The First Hospital of China Medical University, Shenyang, China.
| | | | | |
Collapse
|
36
|
Wang JY, Wang X, Wang XJ, Zheng BZ, Wang Y, Wang X, Liang B. Curcumin inhibits the growth via Wnt/β-catenin pathway in non-small-cell lung cancer cells. Eur Rev Med Pharmacol Sci 2019; 22:7492-7499. [PMID: 30468498 DOI: 10.26355/eurrev_201811_16290] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE In recent decades, the death rate from lung cancer appears to be an increasing yearly trend, particularly for non-small-cell lung cancer (NSCLC). Curcumin is a yellow pigment found in turmeric rhizomes, reported to exhibit various anti-inflammatory, anti-angiogenic, anti-proliferative, and antioxidant properties. Many reports have suggested that curcumin could induce apoptosis in malignant cells, and therefore, has great potential in tumor treatment. However, little is known about the effect of curcumin on NSCLC or its associated mode of action. Therefore, in this study, we explored curcumin's effect on NSCLC and investigated its associated mechanism. MATERIALS AND METHODS The non-small-cell lung cancer (NSCLC) cell line A549 was cultured and subjected to MTT and clonogenic survival assays to assess cell proliferation. Reactive oxygen species (ROS) levels were measured using a Fluostar Omega Spectrofluorimeter. Superoxide dismutase (SOD) and γ-glutamyl cysteine synthetase (γ-GCS) activity in A549 cells were both determined by a commercial determination kit. Expression levels of p-GSK3β (Ser9), c-Myc, cyclin D1, β-catenin α-tubulin, and proliferating cell nuclear antigen (PCNA) were analyzed by Western blot. RESULTS Results of the MTT and clonogenic survival assay indicated that curcumin reduced A549 proliferation. ROS levels and SOD and γ-GCS activities were detected. Curcumin decreased intracellular ROS levels and increased SOD and γ-GCS activity. Meanwhile, the ROS inhibitor N-Acetylcysteine (NAC) reversed the decrease in ROS levels and the increase in SOD and γ-GCS activity. These results indicate that oxidative stress is involved in the curcumin-induced reduction of A549 viability. Curcumin also strongly inhibited β-catenin and p-GSK3β (Ser9) protein expression, as well as the expression of downstream cyclin D1 and c-Myc. Similarly, NAC reversed the inhibition of β-catenin and p-GSK3β (Ser9) protein expression, as well as the expression of downstream cyclin D1 and c-Myc. CONCLUSIONS We showed that curcumin inhibits NSCLC proliferation via the Wnt/β-catenin pathway.
Collapse
Affiliation(s)
- J-Y Wang
- Department of Radiotherapy, Shanxi Province Tumor Hospital, Taiyuan, China.
| | | | | | | | | | | | | |
Collapse
|
37
|
Liu J, Bardawil E, Lin Q, Liang B, Wang W, Wu C, Guan X. Transvaginal Natural Orifice Transluminal Endoscopic Surgery Tubal Reanastomosis: A Novel Route for Tubal Surgery. J Minim Invasive Gynecol 2019. [DOI: 10.1016/j.jmig.2019.09.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Liu J, Kohn J, Sun B, Guan Z, Liang B, Guan X. Transvaginal Natural Orifice Transluminal Endoscopic Surgery Sacrocolpopexy: Tips and Tricks. J Minim Invasive Gynecol 2019. [DOI: 10.1016/j.jmig.2019.09.516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Zhou Y, Yan T, Zhou X, Cao P, Luo C, Zhou L, Xue J, Xu Y, Wang J, Lu Y, Liang B, Gong Y. Correlations between Acute Severe Radiation Pneumonitis Incidence and Pre-Treatment Pulmonary Function Parameters: Analysis Among NSCLC Patients with Moderate Pulmonary Dysfunction Receiving Definitive Concurrent Chemo-Radiotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Liang B. 3. RAMAN PROFILING OF EMBRYO CULTURE MEDIUM TO IDENTIFY ANEUPLOID AND EUPLOID EMBRYOS. Reprod Biomed Online 2019. [DOI: 10.1016/j.rbmo.2019.04.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
41
|
Liang B, Zarikos IM, Bartels WB, Hassanizadeh SM, Clarens A. Effect of Nanoscale Surface Textures on Multiphase Flow Dynamics in Capillaries. Langmuir 2019; 35:7322-7331. [PMID: 31034232 DOI: 10.1021/acs.langmuir.8b04320] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Multiphase flow through porous media is important in a wide range of environmental applications such as enhanced oil recovery and geologic storage of CO2. Recent in situ observations of the three-phase contact line between immiscible fluid phases and solid surfaces suggest that existing models may not fully capture the effects of nanoscale surface textures, impacting flow prediction. To better characterize the role of surface roughness in these systems, spontaneous and forced imbibition experiments were carried out using glass capillaries with modified surface roughness or wettability. Dynamic contact angle and interfacial speed deviation, both resulting from stick-slip flow conditions, were measured to understand the impact these microscale dynamics would have on macroscale flow processes. A 2 k factorial experimental design was used to test the ways in which the dynamic contact angle was impacted by the solid surface properties (e.g., wettability, roughness), ionic strength in the aqueous phase, nonaqueous fluid type (water/Fluorinert and water/dodecane), and the presence/absence of a wetting film prior to the imbibition of the wetting phase. The analysis of variance of spontaneous imbibition results suggests that surface roughness and ionic strength play important roles in controlling dynamic contact angle in porous media, more than other factors tested here. The presence of a water film alone does not affect dynamic contact angle, but its interactions with surface roughness and aqueous chemistry have a statistically significant effect. Both forced imbibition and spontaneous imbibition experiments suggest that nanoscale textures can have a larger impact on flow dynamics than chemical wettability. These experimental results are used to extend the Joos and Wenzel equations relating apparent static and dynamic contact angles to roughness, presence of a water film, and water chemistry. The new empirical equation improves prediction accuracy by taking water film and aqueous chemistry into account, reducing error by up to 50%.
Collapse
Affiliation(s)
- B Liang
- Engineering Systems and Environment , University of Virginia , 351 McCormick Road , Thornton Hall, Charlottesville , Virginia 22904 , United States
| | - I M Zarikos
- Department of Earth Sciences, Faculty of Geosciences , Utrecht University , Utrecht 3508 TA , The Netherlands
| | - W B Bartels
- Department of Earth Sciences, Faculty of Geosciences , Utrecht University , Utrecht 3508 TA , The Netherlands
| | - S M Hassanizadeh
- Department of Earth Sciences, Faculty of Geosciences , Utrecht University , Utrecht 3508 TA , The Netherlands
| | - A Clarens
- Engineering Systems and Environment , University of Virginia , 351 McCormick Road , Thornton Hall, Charlottesville , Virginia 22904 , United States
| |
Collapse
|
42
|
Wang G, Liu Y, Zhang L, Li H, Liang B, Wang J, Zhang X, Chen Z, Zhang H, Xie M, Wang L, Wang G, Brian O. Small Airway Dysfunction Correlates with Perceived Respiratory Symptoms, Neutrophilic Airway Inflammation and Poor Responses to Anti-Asthma Therapy. A64. CLINICAL ASTHMA: ASSESSMENT AND TREATMENT 2019. [DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- G. Wang
- Sichuan University, Chengdu, China
| | - Y. Liu
- Sichuan University, Chengdu, China
| | - L. Zhang
- Sichuan University, Chengdu, China
| | - H. Li
- Sichuan University, Chengdu, China
| | - B. Liang
- Sichuan University, Chengdu, China
| | - J. Wang
- Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - X. Zhang
- Sichaun Univ, West China Hosp, Chengdu, China
| | - Z. Chen
- Pulmonary Department, Zhongshan Hospital, Shanghai, China
| | - H. Zhang
- Sichuan University, Chengdu, China
| | - M. Xie
- Tongji Hospital, wuhan, China
| | - L. Wang
- Sichuan University, Chengdu, China
| | - G. Wang
- West China Hosp, Sichuan Univ, Chengdu, China
| | - O. Brian
- University of Technology Sydney, Ultimo, New Zealand
| |
Collapse
|
43
|
Ni Y, Liang B, Liang Z. Can Corticosteroids Reduce the Mortality of Patients with Severe Sepsis? A Systematic Review and Meta-Analysis. D45. CRITICAL CARE: LOVE IN THE TIME OF CHOLERA - INFECTION AND SEPSIS IDENTIFICATION AND MANAGEMENT 2019. [DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Y. Ni
- Sichuan University West China Hospital, Chengdu, China
| | - B. Liang
- Sichuan University West China Hospital, Chengdu, China
| | - Z. Liang
- Sichuan University West China Hospital, Chengdu, China
| |
Collapse
|
44
|
Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, Arce Vargus F, Sheppard D, Hann BC, Mirza A, Quezada SA, Rosenblum MD, Krummel MF, Balmain A, Akhurst RJ. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer 2019. [PMID: 30832732 DOI: 10.1186/s40425-018-0493-9.pmid:30832732;pmcid:pmc6399967] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023] Open
Abstract
BACKGROUND Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint blockade therapy correlate with tumor mutation load, and intrinsic resistance associates with pre-treatment signatures of epithelial mesenchymal transition (EMT), immunosuppression, macrophage chemotaxis and TGFβ signaling. METHODS To facilitate studies on mechanisms of squamous cell carcinoma (SCC) evasion of checkpoint blockade immunotherapy, we sought to develop a novel panel of murine syngeneic SCC lines reflecting the heterogeneity of human cancer and its responses to immunotherapy. We characterized six Kras-driven cutaneous SCC lines with a range of mutation loads. Following implantation into syngeneic FVB mice, we examined multiple tumor responses to α-PD-1, α-TGFβ or combinatorial therapy, including tumor growth rate and regression, tumor immune cell composition, acquired tumor immunity, and the role of cytotoxic T cells and Tregs in immunotherapy responses. RESULTS We show that α-PD-1 therapy is ineffective in establishing complete regression (CR) of tumors in all six SCC lines, but causes partial tumor growth inhibition of two lines with the highest mutations loads, CCK168 and CCK169. α-TGFβ monotherapy results in 20% CR and 10% CR of established CCK168 and CCK169 tumors respectively, together with acquisition of long-term anti-tumor immunity. α-PD-1 synergizes with α-TGFβ, increasing CR rates to 60% (CCK168) and 20% (CCK169). α-PD-1 therapy enhances CD4 + Treg/CD4 + Th ratios and increases tumor cell pSmad3 expression in CCK168 SCCs, whereas α-TGFβ antibody administration attenuates these effects. We show that α-TGFβ acts in part through suppressing immunosuppressive Tregs induced by α-PD-1, that limit the anti-tumor activity of α-PD-1 monotherapy. Additionally, in vitro and in vivo, α-TGFβ acts directly on the tumor cell to attenuate EMT, to activate a program of gene expression that stimulates immuno-surveillance, including up regulation of genes encoding the tumor cell antigen presentation machinery. CONCLUSIONS We show that α-PD-1 not only initiates a tumor rejection program, but can induce a competing TGFβ-driven immuno-suppressive program. We identify new opportunities for α-PD-1/α-TGFβ combinatorial treatment of SCCs especially those with a high mutation load, high CD4+ T cell content and pSmad3 signaling. Our data form the basis for clinical trial of α-TGFβ/α-PD-1 combination therapy (NCT02947165).
Collapse
MESH Headings
- Antineoplastic Agents, Immunological/pharmacology
- Antineoplastic Agents, Immunological/therapeutic use
- Biomarkers
- CD4 Lymphocyte Count
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/etiology
- Carcinoma, Squamous Cell/metabolism
- Cell Line, Tumor
- Drug Synergism
- Epithelial-Mesenchymal Transition
- Humans
- Immunohistochemistry
- Lymphocyte Count
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Programmed Cell Death 1 Receptor/metabolism
- Signal Transduction/drug effects
- Smad3 Protein/metabolism
- T-Lymphocytes, Helper-Inducer/drug effects
- T-Lymphocytes, Helper-Inducer/immunology
- T-Lymphocytes, Helper-Inducer/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
- Transforming Growth Factor beta/antagonists & inhibitors
Collapse
Affiliation(s)
- E Dodagatta-Marri
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - D S Meyer
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - M Q Reeves
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - R Paniagua
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
- Department of Dermatology, UCSF, San Francisco, CA, USA
| | - M D To
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - M Binnewies
- Department of Pathology, UCSF, San Francisco, CA, USA
| | - M L Broz
- Department of Pathology, UCSF, San Francisco, CA, USA
| | - H Mori
- Center for Comparative Medicine UC Davis, Davis, CA, USA
| | - D Wu
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - M Adoumie
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - R Del Rosario
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - O Li
- Department of Medicine, UCSF, San Francisco, CA, USA
| | - T Buchmann
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - B Liang
- Xoma Corporation, Berkeley, CA, USA
| | - J Malato
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - F Arce Vargus
- Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK
| | | | - B C Hann
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
| | - A Mirza
- Department of Medicine, UCSF, San Francisco, CA, USA
| | - S A Quezada
- Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK
| | - M D Rosenblum
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
- Department of Dermatology, UCSF, San Francisco, CA, USA
| | - M F Krummel
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
- Department of Pathology, UCSF, San Francisco, CA, USA
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
| | - A Balmain
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
- Department of Biochemistry and Biophysics, UCSF, San Francisco, CA, USA
| | - R J Akhurst
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA.
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
- Department of Anatomy, UCSF, San Francisco, CA, USA.
| |
Collapse
|
45
|
Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, Arce Vargus F, Sheppard D, Hann BC, Mirza A, Quezada SA, Rosenblum MD, Krummel MF, Balmain A, Akhurst RJ. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer 2019; 7:62. [PMID: 30832732 PMCID: PMC6399967 DOI: 10.1186/s40425-018-0493-9] [Citation(s) in RCA: 115] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 12/20/2018] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint blockade therapy correlate with tumor mutation load, and intrinsic resistance associates with pre-treatment signatures of epithelial mesenchymal transition (EMT), immunosuppression, macrophage chemotaxis and TGFβ signaling. METHODS To facilitate studies on mechanisms of squamous cell carcinoma (SCC) evasion of checkpoint blockade immunotherapy, we sought to develop a novel panel of murine syngeneic SCC lines reflecting the heterogeneity of human cancer and its responses to immunotherapy. We characterized six Kras-driven cutaneous SCC lines with a range of mutation loads. Following implantation into syngeneic FVB mice, we examined multiple tumor responses to α-PD-1, α-TGFβ or combinatorial therapy, including tumor growth rate and regression, tumor immune cell composition, acquired tumor immunity, and the role of cytotoxic T cells and Tregs in immunotherapy responses. RESULTS We show that α-PD-1 therapy is ineffective in establishing complete regression (CR) of tumors in all six SCC lines, but causes partial tumor growth inhibition of two lines with the highest mutations loads, CCK168 and CCK169. α-TGFβ monotherapy results in 20% CR and 10% CR of established CCK168 and CCK169 tumors respectively, together with acquisition of long-term anti-tumor immunity. α-PD-1 synergizes with α-TGFβ, increasing CR rates to 60% (CCK168) and 20% (CCK169). α-PD-1 therapy enhances CD4 + Treg/CD4 + Th ratios and increases tumor cell pSmad3 expression in CCK168 SCCs, whereas α-TGFβ antibody administration attenuates these effects. We show that α-TGFβ acts in part through suppressing immunosuppressive Tregs induced by α-PD-1, that limit the anti-tumor activity of α-PD-1 monotherapy. Additionally, in vitro and in vivo, α-TGFβ acts directly on the tumor cell to attenuate EMT, to activate a program of gene expression that stimulates immuno-surveillance, including up regulation of genes encoding the tumor cell antigen presentation machinery. CONCLUSIONS We show that α-PD-1 not only initiates a tumor rejection program, but can induce a competing TGFβ-driven immuno-suppressive program. We identify new opportunities for α-PD-1/α-TGFβ combinatorial treatment of SCCs especially those with a high mutation load, high CD4+ T cell content and pSmad3 signaling. Our data form the basis for clinical trial of α-TGFβ/α-PD-1 combination therapy (NCT02947165).
Collapse
MESH Headings
- Antineoplastic Agents, Immunological/pharmacology
- Antineoplastic Agents, Immunological/therapeutic use
- Biomarkers
- CD4 Lymphocyte Count
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/etiology
- Carcinoma, Squamous Cell/metabolism
- Cell Line, Tumor
- Drug Synergism
- Epithelial-Mesenchymal Transition
- Humans
- Immunohistochemistry
- Lymphocyte Count
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Programmed Cell Death 1 Receptor/metabolism
- Signal Transduction/drug effects
- Smad3 Protein/metabolism
- T-Lymphocytes, Helper-Inducer/drug effects
- T-Lymphocytes, Helper-Inducer/immunology
- T-Lymphocytes, Helper-Inducer/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
- Transforming Growth Factor beta/antagonists & inhibitors
Collapse
Affiliation(s)
- E. Dodagatta-Marri
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - D. S. Meyer
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - M. Q. Reeves
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - R. Paniagua
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
- Department of Dermatology, UCSF, San Francisco, CA USA
| | - M. D. To
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - M. Binnewies
- Department of Pathology, UCSF, San Francisco, CA USA
| | - M. L. Broz
- Department of Pathology, UCSF, San Francisco, CA USA
| | - H. Mori
- Center for Comparative Medicine UC Davis, Davis, CA USA
| | - D. Wu
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - M. Adoumie
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - R. Del Rosario
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - O. Li
- Department of Medicine, UCSF, San Francisco, CA USA
| | - T. Buchmann
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - B. Liang
- Xoma Corporation, Berkeley, CA USA
| | - J. Malato
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - F. Arce Vargus
- Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK
| | | | - B. C. Hann
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
| | - A. Mirza
- Department of Medicine, UCSF, San Francisco, CA USA
| | - S. A. Quezada
- Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK
| | - M. D. Rosenblum
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
- Department of Dermatology, UCSF, San Francisco, CA USA
| | - M. F. Krummel
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
- Department of Pathology, UCSF, San Francisco, CA USA
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA USA
| | - A. Balmain
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA USA
- Department of Biochemistry and Biophysics, UCSF, San Francisco, CA USA
| | - R. J. Akhurst
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA USA
- UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA USA
- Department of Anatomy, UCSF, San Francisco, CA USA
| |
Collapse
|
46
|
Liu J, Lin Q, Blazek K, Liang B, Guan X. Transvaginal NOTES Myomectomy: A Novel Route for Uterine Fibroid Removal. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
47
|
Fang L, Wang J, Dai WC, Liang B, Chen HM, Fu XW, Zheng BB, Lei J, Huang CW, Zou SB. Laparoscopic transcystic common bile duct exploration: surgical indications and procedure strategies. Surg Endosc 2018; 32:4742-4748. [PMID: 30298446 DOI: 10.1007/s00464-018-6195-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 04/20/2018] [Indexed: 01/02/2023]
Abstract
BACKGROUND LTCBDE combined with or without modified techniques is safe and efficacious for the management of gallstones and concomitant, even large, common bile duct (CBD) stones. METHODS To describe the surgical indications and procedure strategies of laparoscopic transcystic common bile duct exploration (LTCBDE), a retrospective analysis of 205 patients with concomitant gallstones and CBD stones treated using LTCBDE between June 2008 and June 2015 was performed. Clinical data on disease characteristics, methods for cystic duct incision and CBD stone extraction (with or without laser lithotripsy), and surgical outcomes were collected and reviewed. RESULTS CBD stones were successfully cleared in all patients. No patient was converted to choledochotomy or laparotomy. The cystic duct diameter ranged 3-8 mm, and 85 patients with cystic duct diameter ≥ 5 mm. The mean time for CBD stone extraction was 25.3 min, with the operative time ranged from 63 to 170 min. Lithotripsy was used in 74 (36.1%) patients among which 26 patients with cystic duct diameter ≥ 5 mm. Estimated blood loss during surgery was 10-120 ml per patient, and no intra-operative blood transfusions were needed. The mean postoperative hospital stay was 5.1 (range 3-7) days, and postoperative complications developed in seven patients. No bile duct injury, stricture, remnant, recurrent stones, or other adverse events were observed during the mean follow-up of 8 months. CONCLUSIONS Based on preoperative MRCP and intra-operative IOC findings about cystic duct diameter, the diameter of CBD, CBD stone size, we summarized and proposed the surgical indications and suitable techniques and strategies during LTCBDE.
Collapse
Affiliation(s)
- L Fang
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China.
| | - J Wang
- Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
| | - W C Dai
- Department of General Surgery, Yili Friendship Hospital, Yili, Xinjiang, China
| | - B Liang
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| | - H M Chen
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| | - X W Fu
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| | - B B Zheng
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| | - J Lei
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| | - C W Huang
- Department of Hepatobiliary Surgery, The People's Hospital of Jiangxi, Nanchang, Jiangxi, China
| | - S B Zou
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Mingde Road No. 1, Nanchang, 330000, Jiangxi, China
| |
Collapse
|
48
|
Liang B, Lange S, Mills K, Schulz R, Massad L, Thaker P, Hagemann A, Fuh K, McCourt C, Mutch D, Powell M, Kuroki L. Predictors of severely compromised renal function to aid decision-making for placement of a percutaneous nephrostomy tube(s) or ureteral stent(s) in gynecologic oncology patients. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Liang B, Keshishian V, Liu S, Yi E, Jia D, Zhou Y, Kieffer J, Ye B, Laine R. Processing liquid-feed flame spray pyrolysis synthesized Mg 0.5 Ce 0.2 Zr 1.8 (PO 4 ) 3 nanopowders to free standing thin films and pellets as potential electrolytes in all-solid-state Mg batteries. Electrochim Acta 2018. [DOI: 10.1016/j.electacta.2018.04.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Jiang J, Meng S, Huang S, Ruan Y, Lu X, Li JZ, Wu N, Huang J, Xie Z, Liang B, Deng J, Zhou B, Chen X, Ning C, Liao Y, Wei W, Lai J, Ye L, Wu F, Liang H. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infect 2018; 25:233-241. [PMID: 29698815 DOI: 10.1016/j.cmi.2018.04.018] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 04/17/2018] [Accepted: 04/18/2018] [Indexed: 10/17/2022]
Abstract
OBJECTIVE Talaromyces marneffei is an opportunistic infection with high morbidity among human immunodeficiency virus (HIV)/AIDS patients in Southeast Asia and southern China. Its effects on mortality in HIV/AIDS patients has not been clearly elucidated. METHODS We conducted a retrospective cohort study of hospitalized HIV-infected individuals at the Fourth People's Hospital of Nanning, Guangxi, China during 2012-2015. Kaplan-Meier analyses were used to calculate the cumulative mortality. Cox proportional hazard models and 1:1 propensity score matching (PSM) were used to evaluate the effects of T. marneffei infection on mortality of HIV/AIDS patients. RESULTS In total, 6791 HIV/AIDS patients were included, 1093 of them (16.1%) with documented T. marneffei co-infection. The mortality of T. marneffei-infected patients (25.0 per 100 person-months, 95% CI 21.5-26.7) was the highest among all AIDS-associated complications and was significantly higher than that of T. marneffei-uninfected HIV/AIDS patients (13.8 per 100 person-months, 95% CI 12.5-15.1; adjusted hazard ratio (AHR) 1.80, 95% CI 1.48-2.16). The results using PSM were similar (AHR 4.52 95% CI 2.43-8.42). The mortality of T. marneffei-infected patients was also significantly higher than that of patients without any complications. When stratified by demographic characteristics, T. marneffei infection has higher mortality risk in all stratifications. Co-infection with T. marneffei carries a higher mortality risk in patients at any CD4+ T-cell count. CONCLUSIONS Talaromyces marneffei infection is commonly found in hospitalized HIV/AIDS patients in southern China and was associated with a higher mortality rate than most HIV-associated complications. These results highlight the need for improved diagnosis, treatment and prevention of infection by this neglected fungal pathogen in southern China.
Collapse
Affiliation(s)
- J Jiang
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
| | - S Meng
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China; Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - S Huang
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - Y Ruan
- State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, Chinese Centre for Disease Control and Prevention (China CDC), Beijing, China
| | - X Lu
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - J Z Li
- Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA
| | - N Wu
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - J Huang
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
| | - Z Xie
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - B Liang
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
| | - J Deng
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - B Zhou
- Guangxi Collaborative Innovation Centre for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi, China
| | - X Chen
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China
| | - C Ning
- Guangxi Collaborative Innovation Centre for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi, China
| | - Y Liao
- Guangxi Collaborative Innovation Centre for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi, China
| | - W Wei
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
| | - J Lai
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
| | - L Ye
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
| | - F Wu
- Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
| | - H Liang
- Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China; Guangxi Collaborative Innovation Centre for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi, China.
| |
Collapse
|